Write in a clean editor, then format for Immuno-Oncology Technology in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Immuno-Oncology Technology is a peer-reviewed journal published by Elsevier, covering Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Immuno-Oncology Technology 12 (2023) 45–58.
Formats any DOI in Immuno-Oncology Technology style. No sign-up. |
| Publishes research in | Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses CAR-T cell therapy research Lung Cancer Treatments and Mutations Lung Cancer Research Studies |
| ISSN | 2590-0188 |
| Citation impact (2-yr) | 0.36 |
| h-index | 21 |
| i10-index | 48 |
| Total citations | 1,981 |
| Article processing charge | $2,965 |
| Open access | Yes |
| Top institutions publishing here | Institut Gustave Roussy |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
CD47 is a "don't eat me" signal to phagocytes that is overexpressed on many tumor cells as a potential mechanism for immune surveillance evasion. CD47 and its interaction with signal-regulating protein alpha (SIRPα) on phagocytes is therefore a promising cancer target. Therapeutic antibodies and fusion proteins that block CD47 or SIRPα have been developed and…
•LAG-3 is a highly important next-generation immune checkpoint molecule.•Ninety-seven clinical trials are evaluating at least 16 LAG-3-targeting molecules.•Here we identify preclinical and clinical studies conducted involving LAG-3.•Bispecific LAG-3 molecules are being developed, showing strong capacities.•LAG-3/PD-1 co-blockade is demonstrating encouraging results. Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of…
Characterization of spatial protein expression for multiple targets from a single tissue is difficult to perform, especially due to the limitations of multiplex immunohistochemistry and tissue heterogeneity. Therefore, a new technology is required that permits detailed and simultaneous expression profiling of proteins within a defined region of interest (ROI). To address this unmet need, NanoString…
The recent successes of chimeric antigen receptor T cells in the treatment of hematological malignancies have clearly led to an explosion in the field of adoptive cell therapy for cancer. Current efforts are focused on the translation of this exciting technology to the treatment of solid tumors and the development of allogeneic 'off-the-shelf' therapies. γδ…
Chimeric antigen receptor (CAR) T cell therapy has made significant strides in the treatment of B-cell malignancies, but its application in treating solid tumors still poses significant challenges. Particularly, the widespread use of viral vectors to deliver CAR transgenes into T cells comes with limitations, including high costs and regulatory restrictions, which hinder the translation…
